Gene Regulation
Estrogen receptor α (ERα)-binding super-enhancers drive key mediators that control uterine estrogen responses in mice

https://doi.org/10.1074/jbc.RA120.013666Get rights and content
Under a Creative Commons license
open access

Estrogen receptor α (ERα) modulates gene expression by interacting with chromatin regions that are frequently distal from the promoters of estrogen-regulated genes. Active chromatin-enriched “super-enhancer” (SE) regions, mainly observed in in vitro culture systems, often control production of key cell type–determining transcription factors. Here, we defined super-enhancers that bind to ERα in vivo within hormone-responsive uterine tissue in mice. We found that SEs are already formed prior to estrogen exposure at the onset of puberty. The genes at SEs encoded critical developmental factors, including retinoic acid receptor α (RARA) and homeobox D (HOXD). Using high-throughput chromosome conformation capture (Hi-C) along with DNA sequence analysis, we demonstrate that most SEs are located at a chromatin loop end and that most uterine genes in loop ends associated with these SEs are regulated by estrogen. Although the SEs were formed before puberty, SE-associated genes acquired optimal ERα-dependent expression after reproductive maturity, indicating that pubertal processes that occur after SE assembly and ERα binding are needed for gene responses. Genes associated with these SEs affected key estrogen-mediated uterine functions, including transforming growth factor β (TGFβ) and LIF interleukin-6 family cytokine (LIF) signaling pathways. To the best of our knowledge, this is the first identification of SE interactions that underlie hormonal regulation of genes in uterine tissue and optimal development of estrogen responses in this tissue.

estrogen receptor
gene expression
chromatin modification
transcription
reproduction
chromatin conformation capture
chromatin looping
epigenetic regulation
female reproduction
super-enhancer

Cited by (0)

This article contains supporting information.

Author contributions—S. C. H. and F. J. D. conceptualization; S. C. H. and S. A. G. formal analysis; S. C. H. and S.-P. W. validation; S. C. H., S.-P. W., and F. J. D. investigation; S. C. H. and S. A. G. visualization; S. C. H. and S. A. G. methodology; S. C. H. writing-original draft; S. C. H., S. A. G., S.-P. W., and K. S. K. writing-review and editing; S. A. G. data curation; F. J. D. and K. S. K. resources; K. S. K. funding acquisition; K. S. K. project administration.

Funding and additional information—This work was supported in part by the Intramural Research Program of NIEHS, National Institutes of Health, Grants 1ZIAES070065 (to K. S. K.) and 1ZIAES103311 (to F. J. D.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are:

    ERα

    estrogen receptor α

    KO

    knockout

    ovexed

    ovariectomized

    V

    vehicle

    SE

    super-enhancer

    TE

    typical enhancer

    H3K4Me1

    histone H3 Lys-4 monomethylation

    H3K27Ac

    histone H3 Lys-27 acetylation

    E2

    estradiol

    P4

    progesterone

    LIF

    leukemia-inhibitory factor interleukin-6 family cytokine

    FDR

    false discovery rate

    DEG

    differentially expressed genes

    RA

    retinoic acid

    RAR

    retinoic acid receptor

    SMRT

    silencing mediator of retinoic acid and thyroid hormone receptor.